1YBelow half the group
Rank 35 of 63 funds
Return +19.75%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 35No. 1 is SCBGENOME(E) +51.57%
MFC Health Innovation Fund
Shows where this fund stands in its group. Not investment advice · Data as of 5 Nov 2026
MHEALTHSSF invests through the master fund BGF World Healthscience Fund 101.77%
This fundMHEALTHSSF
The fund that actually investsBGF World Healthscience FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY9.76%
Johnson & Johnson JNJ8.78%Over the past year it trailed half its group; over 3 years it returned +7.76% per year (Below half the group)
No. 1 is SCBGENOME(E) +51.57%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 5 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | MAX |
|---|---|---|---|---|---|---|---|---|
| +12.50% | +3.33% | +5.01% | +12.20% | +11.70% | +21.38% | +19.75% | +25.20% | +23.00% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar |
|---|
Largest drawdown in the selected period −19.55% Previous peak 3 Sep 2024 (NAV 11.7086) → Trough 9 Apr 2025 (NAV 9.4192) · Back to the previous peak on 22 Oct 2026, after 1 year 6 months
Currently 0.00% from the peak NAV of 12.3001 (5 Nov 2026)
Over 3 years, MHEALTHSSF returned 0.54 per unit of volatility, ranking 23 of 37 funds · The highest is TBIOTECH (0.90)
กองทุนมีนโยบายลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศเพียงกองทุนเดียว (Feeder Fund) คือ BGF World Healthscience Fund (กองทุนหลัก) ในชนิดหน่วยลงทุน (share class) “I2” ในสกุลเงินเหรียญดอลลาร์สหรัฐ โดยเฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุนรวม… Its largest holdings are BGF World Healthscience Fund 101.77% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 15 Jun 2022, its NAV has fallen as much as −19.55% from its peak.
Actual total expense ratio (TER) 2.00% a year, against a ceiling of 4.89%. Management fee 1.61%. Front-end fee 0.00%. Back-end fee 0.50%. (Fact sheet 5 Oct 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1,000 THB, subsequent purchases 500 THB. Buy orders accepted until 15:30, sell orders until 15:00, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 30 Sep 2026, 85.00% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · MHEALTHSSF: no dividends, TER 2.00% · MHEALTHG: no dividends, TER 2.00% · MHEALTHPVD: no dividends, TER 2.00%
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
ABBVIE ABBV
Merck & MRK6.03%
Roche ROG4.96%
Thermo Fisher TMO4.21%
Novartis NOVN4.15%
Gilead Sciences GILD3.81%
Amgen AMGN3.36%
Unitedhealth Group UNH3.22%Eli Lilly and Co LLYDiabetes and weight-loss drugs
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
ABBVIE ABBVHospitals, medicines and medical equipment
Merck & MRKHospitals, medicines and medical equipment
Roche ROGHospitals, medicines and medical equipment
Thermo Fisher TMOAn American company selling scientific instruments, reagents and services for laboratories
Novartis NOVNHospitals, medicines and medical equipment
Gilead Sciences GILDA US drug company making HIV treatment and prevention drugs, hepatitis drugs and cancer drugs
Amgen AMGNHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (101.77% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 9 Oct 2026 · fact sheet from BlackRock · Illustrations are for explanation only, not individual stock recommendations
No. 1 is TBIOTECH +22.04% per year
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | −0.8 | +2.0 | −7.0 | −1.7 | +2.7 | +5.3 | −0.6 | +3.5 | −0.0 | +7.6 | +1.7 | · | +12.5* |
| 2025 | +7.7 | −0.5 | −3.3 | −2.9 | −4.1 | +0.9 | −0.5 | +2.0 | −0.2 | +3.4 | +7.6 | −0.8 | +8.7 |
| 2024 | +3.6 | +1.5 | +2.1 | −3.3 | +1.6 | +2.5 | +0.5 | +3.4 | −4.0 | −3.4 | −0.7 | −6.4 | −3.1 |
| 2023 | −2.3 | −2.8 | +2.5 | +2.5 | −4.5 | +4.2 | −0.6 | +0.3 | −3.9 | −4.9 | +3.5 | +4.5 | −2.1 |
| 2022 | · | · | · | · | · | · | · | · | −3.3 | +6.9 | +2.9 | −0.4 | +5.9* |